News from Bayer
May 23, 2022
Not intended for U.S. and UK Media
Two large Xarelto™ studies support effectiveness of dual pathway inhibition in patients with coronary artery disease and/or peripheral artery disease
May 19, 2022
Not intended for U.S. and UK Media
Bayer to present key data across oncology portfolio showcasing significant advances in cancer care at 2022 ASCO Annual Meeting
May 19, 2022
Not intended for U.S. and UK Media
Verquvo™ (vericiguat) approved in China to treat patients with chronic heart failure and reduced ejection fraction